Why Analysts Are Closely Watching Novartis AG (NVS)
Novartis AG (NYSE:NVS) is among the most profitable healthcare stocks to buy.
Novartis A G (NVS)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 14,426 | $1,988,913 | +20% | 0.04% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,809,158 | $249,428,788 | 0.13% | |
| 2. | 1,361,274 | $187,678,847 | 0.03% | |
| 3. | 962,900 | $132,756,440 | 3.57% | |
| 4. | 887,296 | $122,331,561 | 0.16% | |
| 5. | 505,339 | $69,671,133 | 0.79% |
News See All
10 Most Profitable Healthcare Stocks to Buy
By far, the healthcare sector remains among the most resilient and profitable in global equity markets.
Jim Cramer is Optimistic About Novartis' (NVS) Cancer Drug
Pharmaceutical firm Novartis AG (NYSE:NVS)’s shares are up by 44% over the past year and by 7.6% year-to-date. The tail end of 2025 saw several analysts discuss the firm.
14 Stocks on Jim Cramer's Radar
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed OpenAI's ChatGPT and business applications.
Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub
TheFly reported on January 6 that Barclays upgraded NVS to Equal Weight from Underweight with a CHF 120 price target after a coverage transfer.
Top 10 Oncology Stocks to Buy Now
The oncology market in the United States was estimated at $81.34 billion in 2025 and is expected to reach $211.78 billion by 2034 with a compound annual growth rate of 11.75%.
HSBC Lifts PT on Novartis AG (NVS) to $112 From $106
Novartis AG (NYSE:NVS) is one of the most profitable NYSE stocks to buy right now.
11 Most Profitable NYSE Stocks to Buy Right Now
On December 12, Adam Parker, Trivariate Research founder and CEO, appeared on CNBC’s ‘Squawk on the Street’ to talk about his view on the ‘buy high and sell low’ mantra.
Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report
Swiss pharmaceutical giant Novartis AG (NYSE:NVS) has entered into a massive $1.7 billion partnership with British pharmaceutical firm Relation Therapeutics to develop treatments for allergic diseases...
13 Best ADR Stocks to Invest In
ADRs, or American Depository Receipts, are the US-listed securities of foreign firms that allow investors in America to buy and trade the shares within America.
Hedge Fund Resource Center Billionaire Hedge Funds
